Can zoster sine herpete involve the foot (L4‑L5 or S1 dermatome) in an adult, especially those over 50 or who are immunocompromised?

Can Zoster Sine Herpete Involve the Foot?

Yes, zoster sine herpete (ZSH) can absolutely involve the foot through L4-L5 or S1 dermatomes, presenting as radicular pain, dysesthesia, or numbness in the lower extremity without any visible rash.

Understanding Zoster Sine Herpete

Zoster sine herpete is an atypical manifestation of varicella-zoster virus (VZV) reactivation characterized by dermatomal neuropathic pain without the characteristic vesicular rash that defines classic herpes zoster 1. The condition results from VZV reactivation in cranial nerves, spinal nerves (including lumbar and sacral roots), viscera, or autonomic nerves 1.

Clinical Presentation in Lower Extremity Dermatomes

• Any dermatome can be affected by ZSH, including the L4, L5, and S1 distributions that innervate the foot and lower leg 1.
• Patients present with segmental pain and dysesthesia in the affected dermatome without perceptible cutaneous lesions 2.
• The pain is typically unilateral and follows a dermatomal distribution, just as in classic herpes zoster, but the diagnostic visual cue of vesicles is absent 1, 3.

Diagnostic Challenges and Confirmation

The absence of a rash makes clinical diagnosis extremely difficult, often leading to misdiagnosis and delayed treatment 1.

Diagnostic Methods

• VZV DNA PCR analysis is the gold standard for confirming ZSH 3.
  • Can be performed on intact skin scrapings from the affected dermatome, even without visible lesions 3.
  • Real-time PCR can detect significant VZV genome copies from the involved area 2.
• Serologic testing for anti-VZV IgM and IgG antibodies can support the diagnosis 4, 5.
  • A positive anti-VZV IgM indicates acute or recent VZV reactivation 5.
  • IgG antibody demonstration can support the diagnosis in the appropriate clinical context 4.

Key Diagnostic Pitfall

Do not dismiss the possibility of ZSH simply because no rash is visible—the condition is defined by the absence of cutaneous lesions 1. If a patient over 50 years (or immunocompromised at any age) presents with acute unilateral foot pain in a dermatomal distribution, ZSH should be in your differential diagnosis 1, 5.

Treatment Approach

Prompt initiation of antiviral therapy is crucial for minimizing the duration and severity of radicular pain and preventing complications such as postherpetic neuralgia 3.

Antiviral Regimen

• Oral valacyclovir 1000 mg three times daily for 7–10 days is the preferred first-line treatment 6.
• Oral acyclovir 800 mg five times daily for 7–10 days is an effective alternative if valacyclovir is unavailable 6.
• Treatment should be initiated as soon as ZSH is suspected clinically, even before laboratory confirmation, given the time-sensitive nature of antiviral efficacy 3.

Neuropathic Pain Management

• Gabapentin is the first-line agent for acute neuropathic pain, titrated up to 2400 mg per day in divided doses 6.
• Amitriptyline or other tricyclic antidepressants can be used as adjuncts 5.
• For refractory pain, consider adding pregabalin or an 8% capsaicin patch for longer-term management 6.

Special Populations at Higher Risk

Immunocompromised Patients

• Adults over 50 years have increased risk of VZV reactivation, including atypical presentations like ZSH 1.
• Immunocompromised individuals (those on biologics, JAK inhibitors, chemotherapy, or with HIV) are at substantially elevated risk 5.
  • Even immunocompetent patients can develop ZSH, as documented in case reports 5.
• For immunocompromised patients with suspected ZSH, consider intravenous acyclovir 10 mg/kg every 8 hours if the presentation is severe or if oral absorption is uncertain 6.

Prevention Through Vaccination

All adults ≥50 years should receive the recombinant zoster vaccine (Shingrix) to prevent both classic herpes zoster and atypical presentations like ZSH 7.

• Shingrix is administered as a 2-dose series, with the second dose given 2–6 months after the first 7.
• The vaccine demonstrates 97.2% efficacy in preventing herpes zoster across all age groups ≥50 years 7.
• For immunocompromised adults ≥18 years, use a shortened schedule with doses 1–2 months apart 7.
• Only Shingrix (recombinant vaccine) should be used in immunocompromised patients; the live-attenuated Zostavax is absolutely contraindicated 7, 8.

Post-Episode Vaccination

• After recovery from ZSH, patients should receive Shingrix at least 2 months after symptom resolution to prevent recurrence 8.
• The 10-year cumulative recurrence risk is 10.3%, making vaccination essential even after a prior episode 8.

Critical Clinical Pearls

• ZSH can affect any dermatome, including lower extremity distributions (L4, L5, S1) that innervate the foot 1.
• Misdiagnosis and delayed antiviral treatment can lead to severe sequelae including prolonged postherpetic neuralgia, VZV encephalitis, and stroke 1.
• VZV DNA PCR of intact skin scrapings from the painful area is the most reliable confirmatory test when no rash is present 3.
• Start antiviral therapy empirically if clinical suspicion is high, rather than waiting for laboratory confirmation, because the therapeutic window is narrow 3.
• Consider ZSH in any patient with acute dermatomal pain (including foot pain) without an alternative explanation, especially in those over 50 or immunocompromised 1, 4.